HOME >> BIOLOGY >> NEWS
CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell

SAN ANTONIO -- The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. The novel anti-cancer therapy, REOLYSIN, is a living virus, not a chemotherapy drug, that is toxic to cancer cells but not harmful to normal cells. This novel therapy, using a living virus, is the first of its kind available at CTRC. According to Monica Mita, MD, principal investigator at the CTRC Institute for Drug Development, REOLYSINs name was derived from the human reovirus, a mild virus that occurs naturally in the environment.

This novel therapy has shown success because the reovirus replicates in and destroys the cancer cells within the patients body, said Mita. Cancer cells have several molecular and genetic abnormalities. In normal, healthy cells, the reovirus is unable to reproduce because of an enzyme named PKR. The enzyme is suppressed in cancer cells, and therefore the reovirus can replicate in the cancer cell and kill it.

REOLYSIN typifies the true targeted therapy approach that seeks to use fundamental differences between cancer and normal cells as the basis for effective anti-cancer approaches and we are thus very excited about the this study, said Francis Giles, MD, director of the CTRC Institute for Drug Development.

Eligible patients are those who have a bone or soft tissue sarcoma that has spread to the lung and who are deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumors, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

The second patient to enroll in the st
'"/>

Contact: Jill. B. Byrd
jbyrd@ctrc.net
210-450-5550
Cancer Therapy & Research Center (CTRC)
24-Jul-2007


Page: 1 2

Related biology news :

1. Saudi Arabias KAUST names WHOI first research partner
2. Which came first, the moth or the cactus?
3. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
4. Seawater intrusion is the first cause of contamination of coastal aquifers
5. Camera-shy deer caught for first time
6. New joint replacement material developed at MGH put to first clinical use
7. Liverpool amongst first in UK to install unique DNA sequencing technology
8. A first-principles model of early evolution
9. Worlds first X-ray free electron laser is on course to completion
10. Scientists identify first gene linked to scoliosis
11. Which came first: Primates ability to see colorful food or see colorful sex?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, a biopharmaceutical ... annual Inc. 5000 list. The list is the most prestigious ranking of the nation’s ... and for this year’s list, reported three-year revenue growth of 71 percent. , ...
(Date:8/21/2020)... ... August 19, 2020 , ... ... SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than twenty years. Together ... book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and Applications ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both ... NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to gain ... and J&J have annual Research and Development spending in excess of US $10 ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... for the life sciences industry, today announced the release of its signature ... for Medical Science Liaisons (MSLs) and other field medical professionals. , ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this ... the only technology of its kind on the market and we were pleased that ... protective capacity of traditional cultured ingredients, creating a natural way to extend the shelf ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode ... significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES . ... , Bode-CARES provides a turnkey solution that includes a comprehensive ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
Breaking Biology Technology:
Cached News: